Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Yunong Gao"'
Autor:
Jin Li, Jihong Liu, Rutie Yin, Dongling Zou, Hong Zheng, Junning Cao, Zhendong Chen, Wei Sun, Yunong Gao, Songling Zhang, Linjuan Zeng, Ruifang An, Xianping Lu, Shuang Ye, Xiaohua Wu
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-8 (2024)
Abstract Background Platinum-resistant or refractory ovarian cancer is a highly lethal gynecologic disease with limited treatment options. Chiauranib is a novel small-molecule selective inhibitor, which could effectively target multiple pathways incl
Externí odkaz:
https://doaj.org/article/5df2310f3adb4739887160a3fa1dee3f
Publikováno v:
Journal of Ovarian Research, Vol 17, Iss 1, Pp 1-9 (2024)
Abstract Background The efficacy of subsequent therapy after poly-ADP-ribose polymerase (PARP) inhibitor maintenance treatment has raised concerns. Retrospective studies show worse outcomes for platinum-based chemotherapy after progression of PARP in
Externí odkaz:
https://doaj.org/article/f56f3cdae58441df84ae945584799874
Autor:
Yaxin Liu, Wei Wang, Rutie Yin, Youzhong Zhang, Yu Zhang, Keqiang Zhang, Hongming Pan, Ke Wang, Ge Lou, Guiling Li, Ruyan Zhang, Kun Li, Jing Rao, Ben Zhang, Yuting Wang, Quanren Wang, Yunong Gao, Huiping Li
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-10 (2023)
Abstract Background The effect of the combination of an anti-angiogenic agent with a poly (ADP-ribose) polymerase (PARP) inhibitor in cancer treatment is unclear. We assessed the oral combination of fuzuloparib, a PARP inhibitor, and apatinib, a VEGF
Externí odkaz:
https://doaj.org/article/25e642e1f9ec4ff7949cab5b7d9f0206
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background The molecular subtypes of endometrial carcinoma are significantly correlated with survival outcomes and can guide surgical methods and postoperative adjuvant therapy. Among them, the TP53mut subtype has the worst prognosis and can
Externí odkaz:
https://doaj.org/article/8c3af547bb574962bc5c60197139277b
Publikováno v:
BMC Women's Health, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Objective The purpose of this study was to retrospectively assess the pattern, compliance, efficacy and safety of bevacizumab in Chinese ovarian cancer patients. Methods We reviewed the clinicopathological data of patients with histologicall
Externí odkaz:
https://doaj.org/article/67652fdb71c348a09ccd9bce68a548ab
Autor:
Lingfang Xia, Qi Zhou, Yunong Gao, Wenjing Hu, Ge Lou, Hong Sun, Jianqing Zhu, Jin Shu, Xianfeng Zhou, Rong Sun, Xiaohua Wu
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
Patients with recurrent or metastatic cervical cancer have limited therapeutic options. Here the authors report efficacy and safety of camrelizumab (anti-PD-1 antibody) in combination with famitinib (anti-angiogenic agent) in pre-treated recurrent or
Externí odkaz:
https://doaj.org/article/b68826bcc1284eef9a80d3a0217d0034
Autor:
Fang An, Sha Wang, Zhiqi Wang, Lingying Wu, Qiubo Lv, Aiming Lv, Hongwu Wen, Jinsong Han, Yumei Wu, Yunong Gao, Qing Liu, Sumei Wang, Hongxia Li, Luwen Wang, Yanlong Wang, Ruifang Wu, Huan Li, Xiuli Sun
Publikováno v:
Gynecology and Obstetrics Clinical Medicine, Vol 1, Iss 2, Pp 70-74 (2021)
Objective: To compare the degree of agreement and consistency of urodynamic studies (UDS) with low urinary tract symptoms (LUTS) questionnaires for evaluating LUTS in cervical cancer patients following radical hysterectomy (RH) and pelvic lymphadenec
Externí odkaz:
https://doaj.org/article/d6b9d8aeefca4723b3ab9ddddfa6d8df
Autor:
Qi Zhou, Yu Zhang, Jin Peng, Xiaohua Wu, Quanren Wang, Yunong Gao, Ge Lou, Huirong Shi, Rong Sun, Jianqing Zhu, Lingfang Xia, Mei Pan, Wenjing Hu, Xianfeng Zhou
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/13d22eb8ad984afd8107b7f8cdadd482
Autor:
Hong Zheng, Tong Shu, Shan Zhu, Chao Zhang, Min Gao, Nan Zhang, Hongguo Wang, Jie Yuan, Zaixian Tai, Xuefeng Xia, Yuting Yi, Jin Li, Yanfang Guan, Yang Xiang, Yunong Gao
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Platinum-based chemotherapy is still the standard of care after cytoreductive surgery in the first-line treatment for epithelial ovarian cancer. This study aims to integrate novel biomarkers for predicting platinum sensitivity in EOC after initial cy
Externí odkaz:
https://doaj.org/article/4b9ed743a4cf4bb19151642c3cff979f
Publikováno v:
Frontiers in Medicine, Vol 7 (2020)
Mixed serous-endometrioid endometrial carcinoma is a type of endometrial cancer with relatively low incidence. The genetic factors contributing to the tumorigenesis of mixed carcinoma remains to be explored. Here, we report the first identification o
Externí odkaz:
https://doaj.org/article/a27b44a1ca4248348619986c764338ff